Verastem Reports Second Quarter 2016 Financial Results
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the second quarter ended June 30, 2016, and also provided an overview of certain corporate developments.
“We continue to execute on the research and development of our two clinical-stage oncology programs targeting several high unmet need tumor types,” said Robert Forrester, President and Chief Executive Officer of Verastem.
“We continue to execute on the research and development of our two clinical-stage oncology programs targeting several high unmet need tumor types,” said Robert Forrester, President and Chief Executive Officer of Verastem.